Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS019 phase I/II trial in hypereosinophilia
CTR20244691Phase 2Active
- Sponsor
- Enruini
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of JS019 in hypereosinophilic syndrome (HES), sponsored by Enruini. Started Jan 2025; status: active.
02
Drugs
JS019
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on CTR20244691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244691.